The pharmaceutical landscape is witnessing a profound transformation with the ascendance of in vivo cell therapies, a revolutionary approach that…
Read More
Jeito Capital’s Second Fund Closes Above Target, Bolstering European Biopharma Investment to Over €1.6 Billion
Global independent private equity fund Jeito Capital has achieved a significant milestone in European biopharma investment with the successful closure…
Read More
Gilead Executive Sounds Alarm on Limited Innovation Investment Hindering Access to Advanced Therapies
The Netherlands faces significant challenges in ensuring timely patient access to life-changing advanced therapy medicinal products (ATMPs), a situation exacerbated…
Read More
